Meta-analysis of the effects of sometribove zinc suspension on the production and health of lactating dairy cows

Normand R. St-Pierre, George A. Milliken, Dale E. Bauman, Robert J Collier, Joseph S. Hogan, Jan K. Shearer, K. Larry Smith, William W. Thatcher

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective-To provide an updated evaluation of the efficacy and safety of sometribove zinc suspension (rbST-Zn), a form of recombinant bovine somatotropin, in lactating dairy cows. Design-Meta-analysis. Sample-26 studies published in peer-reviewed journals or reviewed by a regulatory agency. Procedures-To be included, a study had to involve the use of the rbST-Zn formulation available to US producers in accordance with the label instructions for treatment initiation (57 to 70 days postpartum), dose (500 mg, q 14 d), and route (SC). Results-For cows treated with rbST-Zn, mean milk, 3.5% fat-corrected milk, fat, and protein yields were increased by 4.00, 4.04, 0.144, and 0.137 kg/d (8.8, 8.89, 0.32, and 0.30 lb/d), respectively; however, the concentration of milk components did not change. Pregnancy proportion for the first 2 breeding cycles was increased by 5.4%, and pregnancy proportion for the duration of the trial was reduced by 5.5% for rbST-Zn-treated cows, compared with proportions for untreated cows. Mean body condition score (1 to 5 scale) was reduced by 0.06 points during the period of rbST-Zn use for treated cows. Administration of rbST-Zn had no effect on milk somatic cell count, the number of days to pregnancy, or inseminations per pregnancy; rates of fetal loss, twins, cystic ovaries, clinical lameness, lameness lesions, or traumatic lesions of the integumentary system; and odds of clinical mastitis or culling. Conclusions and Clinical Relevance-Results indicated that rbST-Zn administration to dairy cows effectively increases milk production with no adverse effects on cow health and well-being.

Original languageEnglish (US)
Pages (from-to)550-564
Number of pages15
JournalJournal of the American Veterinary Medical Association
Volume245
Issue number5
DOIs
StatePublished - 2014

Fingerprint

meta-analysis
Meta-Analysis
Zinc
Suspensions
Milk
dairy cows
zinc
cows
Pregnancy
pregnancy
Health
Integumentary System
Cell Count
lameness
lesions (animal)
Fats
integumentary system
Mastitis
Insemination
Milk Proteins

ASJC Scopus subject areas

  • veterinary(all)
  • Medicine(all)

Cite this

Meta-analysis of the effects of sometribove zinc suspension on the production and health of lactating dairy cows. / St-Pierre, Normand R.; Milliken, George A.; Bauman, Dale E.; Collier, Robert J; Hogan, Joseph S.; Shearer, Jan K.; Larry Smith, K.; Thatcher, William W.

In: Journal of the American Veterinary Medical Association, Vol. 245, No. 5, 2014, p. 550-564.

Research output: Contribution to journalArticle

St-Pierre, Normand R. ; Milliken, George A. ; Bauman, Dale E. ; Collier, Robert J ; Hogan, Joseph S. ; Shearer, Jan K. ; Larry Smith, K. ; Thatcher, William W. / Meta-analysis of the effects of sometribove zinc suspension on the production and health of lactating dairy cows. In: Journal of the American Veterinary Medical Association. 2014 ; Vol. 245, No. 5. pp. 550-564.
@article{18e37920217a4546ad3832f42941b79d,
title = "Meta-analysis of the effects of sometribove zinc suspension on the production and health of lactating dairy cows",
abstract = "Objective-To provide an updated evaluation of the efficacy and safety of sometribove zinc suspension (rbST-Zn), a form of recombinant bovine somatotropin, in lactating dairy cows. Design-Meta-analysis. Sample-26 studies published in peer-reviewed journals or reviewed by a regulatory agency. Procedures-To be included, a study had to involve the use of the rbST-Zn formulation available to US producers in accordance with the label instructions for treatment initiation (57 to 70 days postpartum), dose (500 mg, q 14 d), and route (SC). Results-For cows treated with rbST-Zn, mean milk, 3.5{\%} fat-corrected milk, fat, and protein yields were increased by 4.00, 4.04, 0.144, and 0.137 kg/d (8.8, 8.89, 0.32, and 0.30 lb/d), respectively; however, the concentration of milk components did not change. Pregnancy proportion for the first 2 breeding cycles was increased by 5.4{\%}, and pregnancy proportion for the duration of the trial was reduced by 5.5{\%} for rbST-Zn-treated cows, compared with proportions for untreated cows. Mean body condition score (1 to 5 scale) was reduced by 0.06 points during the period of rbST-Zn use for treated cows. Administration of rbST-Zn had no effect on milk somatic cell count, the number of days to pregnancy, or inseminations per pregnancy; rates of fetal loss, twins, cystic ovaries, clinical lameness, lameness lesions, or traumatic lesions of the integumentary system; and odds of clinical mastitis or culling. Conclusions and Clinical Relevance-Results indicated that rbST-Zn administration to dairy cows effectively increases milk production with no adverse effects on cow health and well-being.",
author = "St-Pierre, {Normand R.} and Milliken, {George A.} and Bauman, {Dale E.} and Collier, {Robert J} and Hogan, {Joseph S.} and Shearer, {Jan K.} and {Larry Smith}, K. and Thatcher, {William W.}",
year = "2014",
doi = "10.2460/javma.245.5.550",
language = "English (US)",
volume = "245",
pages = "550--564",
journal = "Journal of the American Veterinary Medical Association",
issn = "0003-1488",
publisher = "American Veterinary Medical Association",
number = "5",

}

TY - JOUR

T1 - Meta-analysis of the effects of sometribove zinc suspension on the production and health of lactating dairy cows

AU - St-Pierre, Normand R.

AU - Milliken, George A.

AU - Bauman, Dale E.

AU - Collier, Robert J

AU - Hogan, Joseph S.

AU - Shearer, Jan K.

AU - Larry Smith, K.

AU - Thatcher, William W.

PY - 2014

Y1 - 2014

N2 - Objective-To provide an updated evaluation of the efficacy and safety of sometribove zinc suspension (rbST-Zn), a form of recombinant bovine somatotropin, in lactating dairy cows. Design-Meta-analysis. Sample-26 studies published in peer-reviewed journals or reviewed by a regulatory agency. Procedures-To be included, a study had to involve the use of the rbST-Zn formulation available to US producers in accordance with the label instructions for treatment initiation (57 to 70 days postpartum), dose (500 mg, q 14 d), and route (SC). Results-For cows treated with rbST-Zn, mean milk, 3.5% fat-corrected milk, fat, and protein yields were increased by 4.00, 4.04, 0.144, and 0.137 kg/d (8.8, 8.89, 0.32, and 0.30 lb/d), respectively; however, the concentration of milk components did not change. Pregnancy proportion for the first 2 breeding cycles was increased by 5.4%, and pregnancy proportion for the duration of the trial was reduced by 5.5% for rbST-Zn-treated cows, compared with proportions for untreated cows. Mean body condition score (1 to 5 scale) was reduced by 0.06 points during the period of rbST-Zn use for treated cows. Administration of rbST-Zn had no effect on milk somatic cell count, the number of days to pregnancy, or inseminations per pregnancy; rates of fetal loss, twins, cystic ovaries, clinical lameness, lameness lesions, or traumatic lesions of the integumentary system; and odds of clinical mastitis or culling. Conclusions and Clinical Relevance-Results indicated that rbST-Zn administration to dairy cows effectively increases milk production with no adverse effects on cow health and well-being.

AB - Objective-To provide an updated evaluation of the efficacy and safety of sometribove zinc suspension (rbST-Zn), a form of recombinant bovine somatotropin, in lactating dairy cows. Design-Meta-analysis. Sample-26 studies published in peer-reviewed journals or reviewed by a regulatory agency. Procedures-To be included, a study had to involve the use of the rbST-Zn formulation available to US producers in accordance with the label instructions for treatment initiation (57 to 70 days postpartum), dose (500 mg, q 14 d), and route (SC). Results-For cows treated with rbST-Zn, mean milk, 3.5% fat-corrected milk, fat, and protein yields were increased by 4.00, 4.04, 0.144, and 0.137 kg/d (8.8, 8.89, 0.32, and 0.30 lb/d), respectively; however, the concentration of milk components did not change. Pregnancy proportion for the first 2 breeding cycles was increased by 5.4%, and pregnancy proportion for the duration of the trial was reduced by 5.5% for rbST-Zn-treated cows, compared with proportions for untreated cows. Mean body condition score (1 to 5 scale) was reduced by 0.06 points during the period of rbST-Zn use for treated cows. Administration of rbST-Zn had no effect on milk somatic cell count, the number of days to pregnancy, or inseminations per pregnancy; rates of fetal loss, twins, cystic ovaries, clinical lameness, lameness lesions, or traumatic lesions of the integumentary system; and odds of clinical mastitis or culling. Conclusions and Clinical Relevance-Results indicated that rbST-Zn administration to dairy cows effectively increases milk production with no adverse effects on cow health and well-being.

UR - http://www.scopus.com/inward/record.url?scp=84906546035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906546035&partnerID=8YFLogxK

U2 - 10.2460/javma.245.5.550

DO - 10.2460/javma.245.5.550

M3 - Article

C2 - 25148097

AN - SCOPUS:84906546035

VL - 245

SP - 550

EP - 564

JO - Journal of the American Veterinary Medical Association

JF - Journal of the American Veterinary Medical Association

SN - 0003-1488

IS - 5

ER -